Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to better understand the effects of a sodium-glucose transport
protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function
and circulating metabolites (substances created when our bodies break down food, drugs, or
its own tissues) in patients with chronic kidney disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)